LivaNova: Q2 Earnings Insights

Shares of LivaNova LIVN were unchanged after the company reported Q2 results.

Quarterly Results

Earnings per share were down 121.43% year over year to ($0.15), which beat the estimate of ($0.30).

Revenue of $182,200,000 declined by 34.27% from the same period last year, which beat the estimate of $169,730,000.

Looking Ahead

The upcoming fiscal year's EPS expected to be between $1.15 and $1.35.

The upcoming fiscal year's revenue expected to be between $900,000,000 and $1,008,000,000.

Conference Call Details

Date: Jul 29, 2020

Time: 07:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/rznzyc3n

Recent Stock Performance

52-week high: $87.45

52-week low: $33.40

Price action over last quarter: Up 4.69%

Company Profile

U.K.-based LivaNova was born of a combination between Cyberonics in the U.S. and Sorin in Italy. The medical device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. LivaNova derives roughly half of its revenue from the U.S. market, another 21% from Europe, and the remainder from the rest of the world.